Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK Price Scheme Changes To Cost Pharmaceutical Industry £33m

Executive Summary

The government is expecting to reap UK-wide savings of £33m by basing the statutory drug pricing scheme on regular payments on sales rather than price cuts and limiting the maximum prices companies can charge the NHS. The move will bring the scheme more into line with the voluntary PPRS.

You may also be interested in...



New UK Price Deal To Save NHS £930m & Speed Up Access To Innovation

The revised PPRS, which is expected to take effect at the beginning of 2019, will implement a 2% cap on the growth in sales of branded medicines to the NHS that should result in substantial savings on medicines spending. It also provides for faster NICE appraisals for non-cancer drugs, and more flexibility in commercial discussions between companies and the health department.

Changes To UK Price Scheme To Hit Profits, Biosimilar Launches

Proposed changes to the UK statutory scheme for controlling the costs of branded medicines bought by the National Health Service would hit company profits and could deter biosimilar launches.

Changes To UK Price Scheme To Hit Profits, Biosimilar Launches

Proposed changes to the UK statutory scheme for controlling the costs of branded medicines bought by the National Health Service would hit company profits and could deter biosimilar launches.

Related Content

Topics

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel